Geographic Atrophy Market Report 2026

Geographic Atrophy Market Overview

• Geographic Atrophy market size has reached to $2.11 billion in 2025 • Expected to grow to $3.92 billion in 2030 at a compound annual growth rate (CAGR) of 13.1% • Growth Driver: Rising Prevalence Of Age-Related Macular Degeneration Driving Geographic Atrophy Market Growth Due To Aging Population Trends • Market Trend: Innovative Complement Inhibitor Therapy Advancing Treatment Options For Progressive Eye Disease • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Geographic Atrophy Market?

Geographic atrophy is an eye condition that causes gradual vision loss due to damage in the retina. It is a severe form of age-related macular degeneration (AMD) that leads to blind spots in central vision. The main drug types of geographic atrophy are anti-vascular endothelial growth factor (VEGF) therapy, complement inhibitors, neuroprotective agents, others. Complement inhibitors are treatments that regulate an overactive immune response by blocking specific proteins involved in inflammation and cell damage. The various diagnosis includes fundus autofluorescence (FAF), optical coherence tomography angiography (OCT-A), multifocal electroretinography (mfERG). These are administered through various route of administration such as intravitreal, oral, other routes of administration and are distributed through various distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, others.

What Is The Geographic Atrophy Market Growth Forecast?

The geographic atrophy market size is expected to see rapid growth in the next few years. It will grow to $3.92 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to approval of novel therapies, expansion of screening programs, integration of ai-based imaging, increased patient awareness, growth of specialty eye care. Major trends in the forecast period include rising development of complement inhibitor therapies, growing focus on early diagnosis of retinal disorders, increased investment in novel ophthalmic drugs, expansion of imaging technologies for disease monitoring, growing clinical trials for amd treatments.

Global Geographic Atrophy Market Segmentation

1) By Drug Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Complement Inhibitors, Neuroprotective Agents, Other Drug Types 2) By Diagnosis: Fundus Autofluorescence (FAF), Optical Coherence Tomography Angiography (OCT-A), Multifocal Electroretinography (mfERG) 3) By Route Of Administration: Intravitreal, Oral, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels Subsegments: 1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Ranibizumab, Aflibercept, Bevacizumab 2) By Complement Inhibitors: Pegcetacoplan, Lfg316 3) By Neuroprotective Agents: Latanoprost, Brimonidine 4) By Other Drug Types: Steroids, Retinoids, Combination Therapy

What Is The Driver Of The Geographic Atrophy Market?

Increasing prevalence of age-related macular degeneration is expected to propel the growth of the geographic atrophy market going forward. Age-related macular degeneration (AMD) is an eye condition that damages the central part of the retina of the older adults, making it difficult to see fine details. Aging population is the major reason for the prevalence of age-related macular degeneration, as more people are living longer, and the natural aging process causes gradual damage to the eyes, making them more vulnerable to the disease over time. Geographic atrophy treatment support age-related macular degeneration (AMD) patients by slowing the progression of retinal damage and preserving remaining vision. For instance, in January 2024, according to a report published by Medical News Today, a US-based digital media company, the global cases of age-related macular degeneration are expected to rise from 196 million to 288 million by 2040. Therefore, the increasing prevalence of age-related macular degeneration is driving the growth of the geographic atrophy industry.

Key Players In The Global Geographic Atrophy Market

Major companies operating in the geographic atrophy market are Regeneron Pharmaceuticals Inc, Ocugen Inc, Kodiak Sciences Inc, Apellis Pharmaceuticals Inc, Iveric Bio, Graybug Vision, SparingVision, Alkeus Pharmaceuticals, Kiora Pharmaceuticals, Nanoscope Therapeutics, 4D Molecular Therapeutics, Gensight Biologics, BioMarin Pharmaceutical Inc, Nightstar Therapeutics, MeiraGTx, Retinagenix Inc, Adverum Biotechnologies, AGTC Inc, Editas Therapeutics

Global Geographic Atrophy Market Trends and Insights

Major companies operating in the geographic atrophy market are focusing on innovative therapies such as complement inhibitor therapy to develop advanced treatments for geographic atrophy. Complement inhibitor therapy is a treatment that slows down an overactive immune response linked to certain diseases and helps protect healthy cells from damage and reduces disease progression. For instance, in February 2025, Astellas Pharma Inc., a Japan-based pharmaceutical company announced IZERVAY (avacincaptad pegol intravitreal solution) for geographic atrophy approved by the Food and Drug Administration, a US-based government agency. This approval allows IZERVAY to be used without a limitation on the duration of dosing for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This decision provides greater flexibility for managing GA, offering longer-term treatment options for both patients and healthcare providers.

What Are Latest Mergers And Acquisitions In The Geographic Atrophy Market?

In January 2025, Bausch + Lomb Corporation, a US-based pharmaceutical and medical device company that specializes in eye health products, acquired Whitecap Biosciences LLC for an undisclosed amount. With this acquisition, Bausch + Lomb aims to expand its portfolio of innovative eye health solutions by incorporating Whitecap Biosciences' expertise in advanced ocular therapeutics. Whitecap Biosciences LLC is a US-based pharmaceutical company that specializes in developing novel therapies for ophthalmic diseases including geographic atrophy.

Regional Outlook

North America was the largest region in the geographic atrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Geographic Atrophy Market?

The geographic atrophy market consists of revenues earned by entities by providing gene therapies, and stem cell therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The geographic atrophy market also includes sales of artificial retinas, and medication. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Geographic Atrophy Market Report 2026?

The geographic atrophy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the geographic atrophy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.